



# BAC Frequently Asked Questions



cmAngio is FDA-cleared, proprietary, artificial intelligence (AI) based software intended to detect the presence or absence of Breast Arterial Calcifications (BAC), an incidental finding in both Full Field Digital Mammogram (FFDM) and Digital Breast Tomosynthesis (DBT) screening mammograms.

Why does cmAngio matter?

Based on current research and published literature, Breast Arterial Calcifications (BAC) are currently considered to be a benign incidental finding without defined clinical importance to breast cancer screening. However, there is growing evidence that it is associated with other vascular calcifications and associated clinical outcomes. Patients identified with BAC may be candidates for additional clinical evaluation of general health.

---

How is it detected on mammograms?

The cmAngio software reads the mammograms to determine the presence or absence and location of breast arterial calcification.

---


Are there ages where this assessment makes sense?

By incorporating BAC screening into regular mammography appointments, healthcare providers can track the progression or stabilization of breast arterial calcifications. This ongoing assessment may offer critical insights into overall risk factors and the overall health status of patients, making it a beneficial practice for any age.

---

Is it covered by insurance?

Like many new healthcare products, cmAngio is not currently covered by insurance. However, the out-of-pocket cost may be paid using your HSA or FSA account.



---

To learn more about the device and research please visit:  
<http://www.curemetrix.com>